Fulcrum Therapeutics Inc (NASDAQ: FULC) has experienced a decline in its stock price by -1.09 compared to its previous closing price of 6.43. However, the company has seen a fall of -6.88% in its stock price over the last five trading days. globenewswire.com reported 2025-06-06 that CAMBRIDGE, Mass., June 06, 2025 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to a new employee. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).
Is It Worth Investing in Fulcrum Therapeutics Inc (NASDAQ: FULC) Right Now?
Additionally, the 36-month beta value for FULC is 2.42. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for FULC is 47.85M and currently, short sellers hold a 11.87% ratio of that float. The average trading volume of FULC on June 19, 2025 was 551.31K shares.
FULC’s Market Performance
The stock of Fulcrum Therapeutics Inc (FULC) has seen a -6.88% decrease in the past week, with a -8.23% drop in the past month, and a 114.14% gain in the past quarter. The volatility ratio for the week is 2.82%, and the volatility levels for the past 30 days are at 3.15% for FULC. The simple moving average for the last 20 days is -6.10% for FULC’s stock, with a simple moving average of 49.48% for the last 200 days.
Analysts’ Opinion of FULC
Many brokerage firms have already submitted their reports for FULC stocks, with Leerink Partners repeating the rating for FULC by listing it as a “Outperform.” The predicted price for FULC in the upcoming period, according to Leerink Partners is $12 based on the research report published on May 23, 2025 of the current year 2025.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see FULC reach a price target of $10. The rating they have provided for FULC stocks is “Overweight” according to the report published on May 15th, 2025.
H.C. Wainwright gave a rating of “Neutral” to FULC, setting the target price at $4 in the report published on September 13th of the previous year.
FULC Trading at 18.50% from the 50-Day Moving Average
After a stumble in the market that brought FULC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.22% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FULC starting from Tourangeau Greg, who sale 498 shares at the price of $5.06 back on May 08 ’25. After this action, Tourangeau Greg now owns 14,062 shares of Fulcrum Therapeutics Inc, valued at $2,520 using the latest closing price.
Stock Fundamentals for FULC
Current profitability levels for the company are sitting at:
- -0.16 for the present operating margin
- 0.78 for the gross margin
The net margin for Fulcrum Therapeutics Inc stands at -0.01. The total capital return value is set at -0.05. Equity return is now at value -0.23, with -0.21 for asset returns.
Based on Fulcrum Therapeutics Inc (FULC), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at 0.96.
Currently, EBITDA for the company is -18.24 million with net debt to EBITDA at 5.37. When we switch over and look at the enterprise to sales, we see a ratio of 3.87. The receivables turnover for the company is 81.72for trailing twelve months and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 28.71.
Conclusion
In conclusion, Fulcrum Therapeutics Inc (FULC) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
